Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06555822 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate Multiple Ascending Doses and Relative Bioavailability of AZD5004 in Healthy Participants
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT06555822 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 31 participants.
The verdict
NCT06555822, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the safety, tolerability, and pharmacokinetic (PK) of AZD5004 administered as multiple oral doses in healthy participants and to compare the relative bioavailability of two oral tablet strengths of AZD5004.
Interventions
- DRUG Placebo
- DRUG AZD5004
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2024-08-15 |
| Est. Completion | 2025-03-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06555822
The ClinicalTrials.gov registry entry for NCT06555822 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06555822 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06555822 about?
NCT06555822 is a clinical study titled "A Study to Investigate Multiple Ascending Doses and Relative Bioavailability of AZD5004 in Healthy Participants". The main purpose of this study is to assess the safety, tolerability, and pharmacokinetic (PK) of AZD5004 administered as multiple oral doses in healthy participants and to compare the relative bioavailability of two oral tablet strengths of AZD5004.
What is the current status of trial NCT06555822?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2024-08-15. Estimated completion is 2025-03-06.
What interventions are being tested in trial NCT06555822?
The interventions under investigation include: Placebo (DRUG), AZD5004 (DRUG).
Who is sponsoring clinical trial NCT06555822?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.